Psychiatr. praxi. 2012;13(4):152-155

Pharmacotherapy of anxiety. Have we other possibilities than SSRI?

MUDr.Sylva Racková, Ph.D., MUDr.Luboš Janů, Ph.D.2
1 Psychiatrická klinika LF UK v Plzni

Anxiety disorders with lifetime prevalence 28.8 % belong among the most common illnesses. The short overview of pharmacotherapeutical

possibilities other than SSRI´s (selective serotonine reuptake inhibitors) with respect to the fast onset and long-term efficacy

(agomelatine, venlafaxine, duloxetine, pregabaline and some older antidepressants) are introduced in this article. Pharmaceuticals

marketed in Czech republic with proved efficacy in double blind, placebo controlled studies of the most commen anxiety disorders

(generalized anxiety disorder, social phobia and panic disorder) are mentioned in this summary.

Keywords: generalized anxiety disorder, panic disorder, social phobia, pharmacotherapy, antidepressants, anxiolytics

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Racková S, Janů L, PD. Pharmacotherapy of anxiety. Have we other possibilities than SSRI? Psychiatr. praxi. 2012;13(4):152-155.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kessler RC, Berglund PA, Demler O, Jin R, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005; 62(6): 593-602. Go to original source... Go to PubMed...
    2. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005; 62(6): 617-627. Go to original source... Go to PubMed...
    3. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve month use of mental health services in the United States. Arch Gen Psychiatry 2005; 62(6): 629-640. Go to original source... Go to PubMed...
    4. Roy-Byrne PP, Davidson KW, Kessler RC, Asmundson GJG, Goodwin RD, Kubzansky L, Lydiard RB, Massie MJ, Katon W, Laden SK, Stein MB. Anxiety disorders and comorbid medical illness, Focus 2008; 6(4): 467-485. Go to original source...
    5. Lamers F, van Oppen P, Comijs HC, Smit JH, Spinhoven P, van Balkom AJ, Nolen WA, Zitman FG, Beekman AT, Penninx BW. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 2011; 72(3): 341-348. Go to original source... Go to PubMed...
    6. Marquenie LA, Schadé A, van Balkom AJ, Comijs HC, de Graaf R, Vollebergh W, van Dyck R, van den Brink W. Origin of the comorbidity of anxiety disorders and alcohol dependence: findings of a general population study. Eur Addict Res 2007; 13(1): 39-49. Go to original source... Go to PubMed...
    7. Meoni P, Hackett D, Lader M. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder. Depression and Anxiety 2004; 19(2): 127-132. Go to original source... Go to PubMed...
    8. Loo H, Hale A, D´haenen H. Determination of the dose of agometaline, a melatoninergic agonist a selective 5-HT2C antagonist, in the treatment major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239-247. Go to original source... Go to PubMed...
    9. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized double-blind study. Int Clin Psychopharmacol 2010; 25: 305-314. Go to original source... Go to PubMed...
    10. Kasper S, Hajak G, Wulff K. Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchov F, Baylé FJ. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized double-blind comparison with sertraline. J Clin Psychiatry 2010; 71(2): 109-120. Go to original source... Go to PubMed...
    11. Stein D, Ahokas A, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder. A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 561-566. Go to original source... Go to PubMed...
    12. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50(11): 884-895. Go to original source... Go to PubMed...
    13. Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, Fabre LF, Pecknold JC, Smith WT, Rickels K. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsychology 1 9 92; 25(4): 193-201. Go to PubMed...
    14. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev 2010; 8(12): CD006815. Go to original source... Go to PubMed...
    15. Boschen MJ. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. Can J Psychiatry 2011; 56(9): 558-566. Go to original source... Go to PubMed...
    16. Canton J, Scott KM, Glue P. Optimal treatment of social phobia, systematic review and metaanalysis. Neuropsychiatr Dis Treat 2012; 8: 203-215. Go to original source...
    17. Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 352-359. Go to original source... Go to PubMed...
    18. Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 2007; 194(2): 233-242. Go to original source... Go to PubMed...
    19. Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. Journal of Clinical Psychiatry 2002; 63(1): 31-37. Go to original source... Go to PubMed...
    20. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: A placebo-controlled trial. J Clin Psychopharmacology 1992; 12(4): 251-261. Go to original source...
    21. Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Gil FP, Leiberich PK, Rother N, Bachler E, Fartacek R, Kaplan P, Tritt K, Mitterlehner FM, Anvar J, Rother WK, Loew TH, Egger C. Mirtazapine Treatment of Social Phobia in Women: A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychopharmacology 2005; 25(6): 580-583. Go to original source... Go to PubMed...
    22. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollak M, Stein MB, Lydiard RB, FuttererR, Robinson P, Slomkowski M, DuBoff E, Phelps M, Janney CA, Werth JL. Efficacy of the anxiolytic pregabalin in social anxiety disorder. J Clin Psychopharmacol 2004; 24(2): 141-149. Go to original source... Go to PubMed...
    23. Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Disord 2010; 123(1-3): 9-16. Go to original source... Go to PubMed...
    24. Montgomery SA, Mahé V, Haudiquet V, Hackett D. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. J Clin Psychopharmacol 2002; 22(6): 561-567. Go to original source... Go to PubMed...
    25. Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM. Duloxetine treatment for relapse prevention in adults in generalised anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2008; 18(9): 673-681. Go to original source... Go to PubMed...
    26. Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008; 23: 18-28. Go to original source... Go to PubMed...
    27. Stein D, Ahokas A, Allgulander C, Soegaard J, Bitter I, Lehtments A, Wahlstedt K, Van Amerigen M. Long-term treatment with agomelatine: prevention of relapse in patients generalized anxiety disorder over 6 months. Eur Psychiatry 2011; 26(Suppl 1): 181. Go to original source...
    28. Stein MB, Pollack MH, Bystitsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Pharmacopsychiatry 2005; 177(3): 280-288. Go to original source... Go to PubMed...
    29. Stein DJ, Cameron A, Amrein R, Montgomery SA; Social Phobia Clinical Study Group. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. J Clin Psychopharmacol 2002; 12(4): 161-170. Go to original source... Go to PubMed...
    30. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161: 353-360. Go to original source... Go to PubMed...
    31. Greist JH, Liu-Dumaw M, Schweizer E, Fetlner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol 2011; 26: 243-251. Go to original source... Go to PubMed...
    32. Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry 2007; 68(1): 58-68. Go to original source... Go to PubMed...
    33. Mavissakalian MR, Perel JM. 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. Ann Clin Psychiatry 2001; 13(2): 63-67. Go to original source...
    34. Martin JL, Sainz-Padro M, Furukawa TA, Martín-Sánchez E, Seoane T, Galán C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol 2007; 21(7): 774-782. Go to original source... Go to PubMed...
    35. Lader M. Effectiveness of benzodiazepines: do they work or not? Expert Review Neurotherapeutics 2008; 8(8): 1189-1191. Go to original source... Go to PubMed...
    36. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993; 13(4): 257-263. Go to original source... Go to PubMed...
    37. Montgomery SA, Tobias K, Zornberg G, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67(5): 771-782. Go to original source... Go to PubMed...
    38. Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial, Int Clin Psychopharmacol 2009; 24(2): 87-96. Go to original source... Go to PubMed...
    39. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Möller HJ. WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Int J Psychiatry Clin Pract. 2012; 16(2): 77-84. Epub 2012 Apr 30. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Go to original source... Go to PubMed...
    40. Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ. Time to relapse after 6 and 12 months´treatment of generalised anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry 2010; 67(12): 1274-1281. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.